18 September 2023 - KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical anti-tumour activity ...
12 September 2023 - Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company’s third clinical program to receive fast ...
12 September 2023 - Affimed today announced that the FDA has granted fast track designation to the combination of its innate ...
8 September 2023 - Mendus today announced that it has received fast track designation from the US FDA for the Company’s ...
4 September 2023 - Abliva today announced that the company’s lead candidate KL1333 has received fast track designation from the ...
24 August 2023 - TSHA-102 has also received orphan drug and rare paediatric disease designations from the US FDA and ...
24 August 2023 - Fast Track designation accelerates the path to US submission for the investigational monoclonal antibody in patients with ...
24 August 2023 - Fast Track designation accelerates Nectero EAST System’s path to FDA regulatory review of a treatment for patients ...
23 August 2023 - Comanche Biopharma today announced that they have received fast track designation from the US FDA for ...
11 August 2023 - The Company is currently evaluating the safety/tolerability and efficacy of an investigational drug candidate with disease-modifying potential ...
1 August 2023 - PYC Therapeutics has received fast track designation from the US FDA for a new drug aimed ...
31 July 2023 - Invectys is pleased to announce the US FDA has granted fast track designation to its revolutionary ...
20 July 2023 - On track for proof of concept results in HAE patients in mid 2024. ...
20 July 2023 - EBT-101 is a potentially curative, one time CRISPR based treatment which makes two cuts in integrated retroviral ...
19 July 2023 - Ambrx Biopharma today announced that the US FDA has granted fast track designation to Ambrx’s proprietary anti-PSMA ...